NexGard Spectra®

NexGard Spectra® is a prescription only medicine. This site is provided as an information service for veterinary professionals working in the UK. Please tick ‘I’m a veterinary professional’ to confirm that you are a veterinary professional working in the UK (e.g. veterinary surgeon, veterinary nurse or veterinary student).

Enter site No I don’t agree
Slide 1

Broad-spectrum protection in a single, monthly, tasty chew*

  • FLEAS
  • TICKS
  • MITES
  • LUNGWORM
  • ROUNDWORMS
Find out more
slide 2

A monthly treat

A tasty chew that dogs will love

Watch the video to see what dogs think
slide 3

Ideal for puppies too

Suitable for lifelong treatment

Find out more
slide 4

Suitable for breeding bitches

Can be used in breeding, pregnant and lactating bitches**

Find out more

Parasite protection for dogs couldn’t be easier

One monthly, tasty chew provides broad-spectrum parasite cover
against these key parasites:†

 

Click on each parasite to find out more

dog parasites

AFOXOLANER

  • Flea

    Eliminates
    fleas

  • ticks

    Terminates
    ticks

  • Mites

    Manages
    mites†

MILBEMYCIN OXIME

  • Controls
    roundworms

    Roundworm

  • Prevents
    lungworm
    disease

    Lungworm disease

Also covers

  • Hookworms
  • Whipworm
  • Heartworm
  • Eyeworm

NexGard Spectra® kills fleas

The afoxolaner effect:‡

clock

Fleas start dying after
just 2 hours1

clock

All fleas are dead within 6 hours1

Flea

Kills fleas before they can lay eggs2

‡ Data from NexGard® studies1


References:

  1. Beugnet F, deVos C, Liebenberg J, et al. Afoxolaner against fleas: immediate efficacy and resultant mortality after short exposure on dogs. Parasite 2014;21:42.

  2. EMA. European Public Assessment Report (EPAR): NexGard Spectra chewable tablets for dogs (afoxolaner and milbemycin oxime). European Medicines Agency, London.

 

NexGard Spectra® kills ticks – in time

The afoxolaner effect:‡

24 hours time

Ticks killed within
24 hours1

Tick

Kills ticks before the transmission window for Lyme disease and babesiosis2,3

‡ Data from NexGard® studies1


References:

  1. Halos L, Lebon W, Chalvet-Monfray K, et al. Immediate efficacy and persistent speed of kill of a novel oral formulation of afoxolaner (NexGard®) against induced infestations with Ixodes ricinus ticks. Parasit Vectors 2014;7:452.

  2. Wright I. What do dog owners need from tick protection? Vet Times 2018;48:10-11.

  3. Beugnet F, Halos L, Guillot J. Textbook of Clinical Parasitology in dogs and cats Servet editorial – Grupo Asís Biomedia, S.L.; 2018.

NexGard Spectra® manages mites§

Sarcoptic mange

100% EFFICACY

after 2 monthly treatments51

100% EFFICACY before

Before

100% EFFICACY after

After

Demodicosis

98-100% EFFICACY

after 3 monthly treatments§2,3

98–100% EFFICACY before

Before

98–100% EFFICACY after

After

§ NexGard Spectra®’s mite indication is for treatment of sarcoptic mange and demodicosis. NexGard Spectra® does not cover ear mites. Refer to SPC for specific treatment regimes.
 

References:

  1. Hampel V, Knaus M, Schafer J, et al. Treatment of canine sarcoptic mange with afoxolaner (NexGard®) and afoxolaner plus milbemycin oxime (NexGard Spectra®) chewable tablets: efficacy under field conditions in Portugal and Germany. Parasite 2018;25:63.
  2. Rehbein S, de Vos C, Beugnet FC, et al. Efficacy of Once-Monthly Doses of Oral Afoxolaner and Afoxolaner/Milbemycin Oxime in a Well-Controlled Study for the Treatment of Canine Generalized Demodicosis. Open Journal of Veterinary Medicine 2018;08:250–265.
  3. Lebon W, Beccati M, Bourdeau P, et al. Efficacy of two formulations of afoxolaner (NexGard® and NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe. Parasit Vectors 2018;11:506.

Roundworms - a forgotten family risk for pet owners?

Toxocara is an increasing public health concern

Eggs are widespread
  • Eggs are very commonly found in public parks and gardens

    Eggs are very commonly found in public parks and gardens1

  • 1 in 5 dogs has eggs on their paws and coats

    1 in 5 dogs has eggs on their paws and coats2

Children are especially at risk
  • 27% of children have Toxocara antibodies

    27% of children have Toxocara antibodies3

  • Exposed children score lower in maths and reading assessments

    Exposed children score lower in maths and reading assessments4

Increased disease risks
  • Risk of epilepsy is almost doubled

    Risk of epilepsy is almost doubled5

  • Risk of asthma is almost tripled

    Risk of asthma is almost tripled6

References:

  1. Morgan E. Toxocara canis: how safe is that sandpit? Vet Times 2018;48:6–7.
  2. Panova OA, Khrustalev AV. Dog walking brings Toxocara eggs to people’s homes. Veterinary Parasitology 2018;262:16–19.
  3. Ree GH, Voller A, Rowland HA. Toxocariasis in the British Isles 1982-3. Br Med J (Clin Res Ed) 1984;288:628–629.
  4. Walsh MG, Haseeb MA. Reduced cognitive function in children with toxocariasis in a nationally representative sample of the United States. Int J Parasitol 2012;42:1159–1163.
  5. Quattrocchi G, Nicoletti A, Marin B, et al. Toxocariasis and epilepsy: systematic review and meta-analysis. PLoS Negl Trop Dis 2012;6:e1775.
  6. Li L, Gao W, Yang X, et al. Asthma and toxocariasis. Ann Allergy Asthma Immunol 2014;113:187–192.

NexGard Spectra® prevents lungworm disease

Monthly administration of NexGard Spectra® prevents
angiostrongylosis and controls environmental contamination1,2

94.9%

Reduction of lungworm burden2

99.9%

Reduction of larval shedding2

References:

  1. EMA. European Public Assessment Report (EPAR): NexGard Spectra® chewable tablets for dogs (afoxolaner and milbemycin oxime). European Medicines Agency, London.

  2. Lebon W, Tielemans E, Rehbein S, et al. Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs. Parasit Vectors 2016;9:485.

 

When given the choice of both, 9/10 dogs preferred NexGard Spectra®1,2

Study design

Study 1.

Dogs were offered NexGard Spectra® and Simparica Trio™simultaneously, one in each hand.

 

Study 2.

Dogs were offered NexGard Spectra® and Simparica Trio™simultaneously, one in each hand.

  • For each study this was repeated once a day over four consecutive days.
  • The hands offering the product were changed each subsequent day, e.g. right hand on day 1 and left hand on day 2.
  • Dogs were allowed to sniff hands, then after choosing a product the other hand was closed.
  • Dogs were observed for 1 minute and it was recorded if the product they chose was consumed. Preference was recorded if one product was consumed more than the other over the four days. No preference was recorded if the product was not consumed or if the choice was equal between the products.

NexGard Spectra® is also suitable for puppies

  • Can be used on puppies

    Can be used on puppies
    from just 8 weeks of age and from 1.35 kg

  • Five weight ranges

    Five weight ranges
    enable appropriate monthly dosing as puppies grow

  • Monthly dosing follows ESCCAP

    Monthly dosing follows ESCCAP‡ 
    puppy roundworming recommendations

For more information, read the full vet brochure

NexGard Spectra® offers benefits for owners and practices too

Explore the latest...

Owner materials

Handy resources, like posters for your veterinary practice, and materials to support your client communications.

Click to view more info
Owner materials

Puppy campaign

Engage with new puppy owner clients, helping to keep their new family member happy and healthy while building a lifelong connection with your practice.

Click to view more info
Puppy campaign

Introducing Parassess®

A FREE online, easy-to-use parasite risk checker that helps owners to help you assess their dog’s individual risk. Enables a timely, risk-based prescribing decision in your busy practice.

Learn more
Explore Parassess
  • Owner materials
  • Puppy campaign
  • Parassess risk checker

* NexGard Spectra® is indicated for the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease, angiostrongylosis and/or treatment of gastrointestinal nematode infestations is indicated. NexGard Spectra®’s mite indication is for treatment of sarcoptic mange and demodicosis. NexGard Spectra® does not cover tapeworm.
** The safety of the veterinary medicinal product has not been established in breeding males. In breeding males, use only according to the benefit-risk assessment by the responsible veterinarian.
† NexGard Spectra® also covers heartworm, hookworms, whipworm and eyeworm. NexGard Spectra®’s mite indication is for treatment of sarcoptic mange, demodicosis and otodectes cynotis. NexGard Spectra® does not cover tapeworm.
‡ European Scientific Counsel Companion Animal Parasites.

1Perier N, Carithers DS, Everett WR, et al. Preference of Dogs between Two Oral Formulations of Endectoparasiticides:Nexgard Spectra® (Afoxolaner and Milbemycin Oxime) and Simparica Trio™ (Sarolaner, Moxidectin and Pyrantel). Open Journal of Veterinary Medicine 2020;10:155-16. 

2Perier N, Carithers DS, Everettt WR, et al. Preference in Dogs of Two Oral Endectoparasiticide Formulations: NexGard Spectra® (Afoxolaner and Milbemycin Oxime) and Credelio® Plus (Lotilaner and Milbemycin Oxime). Open Journal of Veterinary Medicine 2021; 11, 289-298.

NexGard Spectra® contains afoxolaner and milbemycin oxime. UK: POM-V. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical). Email: vetenquiries@boehringer-ingelheim.com. NexGard Spectra® is a registered trademark of Boehringer Ingelheim Animal Health France SCS, used under licence. ©2024 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation April 2024. UI-CAN-0028-2024. Use Medicines Responsibly.